Welcome to our dedicated page for Caris Life Sciences news (Ticker: CAI), a resource for investors and traders seeking the latest updates and insights on Caris Life Sciences stock.
Caris Life Sciences, Inc. develops and commercializes AI-enabled precision medicine solutions built around comprehensive molecular profiling, next-generation sequencing and machine learning. The company’s diagnostics and data platform use Whole Genome, Whole Exome and Whole Transcriptome Sequencing, a multimodal clinico-genomic database and high-performance computing to support early detection, diagnosis, monitoring, therapy selection and drug development.
Company announcements commonly address molecular profiling services, clinical therapy selection volume, product launches and regulatory or reimbursement actions for tests such as Caris Assure, Caris MI Clarity and Caris ChromoSeq. Other recurring developments include peer-reviewed validation of Caris AI Insights, Caris Precision Oncology Alliance collaborations, conference presentations and quarterly financial results.
Caris Life Sciences (NASDAQ: CAI) launched the “Behind the Diagnosis” campaign highlighting real patients whose treatment was informed by Caris’ comprehensive genomic profiling and AI.
The first story features Caris GPSai correcting a presumed metastatic breast cancer to highly treatable Hodgkin lymphoma, and references FDA-approved MI Cancer Seek and clinical data on GPSai’s impact on misdiagnosis and therapy eligibility.
Caris Life Sciences (NASDAQ: CAI) published a study in The Oncologist on the Caris Lookback Program, which continuously re-evaluates prior Caris MI Cancer Seek tests as new biomarker‑drug approvals emerge.
From >483,000 profiles, the program found 13,293 patients potentially eligible for newly approved targeted therapies across 10 tumor types, about 40% in non‑small cell lung cancer, using multi‑modal profiling such as WES, WTS and IHC. MI Cancer Seek is described as the first and only simultaneous WES+WTS‑based assay with FDA‑approved CDx indications for solid tumors, available for adults and children aged 1 and older.
Caris Life Sciences (NASDAQ:CAI) reported study results showing that ultra-deep Whole Exome Sequencing (WES) measurement of tumor mutational burden (TMB) better predicts pembrolizumab benefit than targeted gene panels.
Among 26,756 pembrolizumab-treated patients, targeted panels misclassified TMB in 10–15% of cases, while WES-based TMB was linked to longer overall survival in key subgroups.
Caris’ FDA-approved MI Cancer Seek assay delivers simultaneous WES and Whole Transcriptome Sequencing with quantitative TMB reporting for solid tumors.
Caris Life Sciences (NASDAQ: CAI) submitted an application to the New York State Department of Health CLEP/Wadsworth Center to seek authorization to perform Caris Assure blood-based molecular profiling on specimens from New York State patients.
Caris Assure uses circulating nucleic acids sequencing to analyze the whole exome and whole transcriptome of 22,000 genes, reporting tumor alterations, clonal hematopoiesis, inherited variants, pharmacogenomics, MSI and TMB. Authorization is pending; Caris will only test New York specimens if CLEP approval is granted.
Caris Life Sciences (Nasdaq: CAI) reported Q1 2026 results for the quarter ended March 31, 2026. Total revenue $216.2M, up 79% year‑over‑year; molecular profiling revenue $210.8M. Reported gross margin 65%, net loss $0.5M, and Adjusted EBITDA $26.2M. Q1 operating cash flow was $32.9M; free cash flow $22.5M. Company reaffirmed 2026 revenue guidance of $1.0–$1.02B and ~20% clinical therapy selection volume growth.
Operational highlights include ~52,800 clinical therapy selection cases, Achieve 1 study results, new assay launches, and a $400M refinanced credit facility.
Caris Life Sciences (NASDAQ: CAI) launched Caris MI Clarity, an AI-powered prognostic test that predicts both early (0–5 years) and late (5–15 years) distant recurrence risk for postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer at diagnosis. Results are typically returned within 3 business days. The model was trained on Caris' multimodal dataset and validated using samples from national trials including TAILORx and NSABP B-42. The test uses digitized H&E slides plus clinical inputs and does not require genomic sequencing, enabling scalability from routine pathology specimens.
Caris Life Sciences (NASDAQ: CAI) announced on May 4, 2026 that Caris ChromoSeq received MolDX approval, a Medicare molecular diagnostic review by Palmetto GBA that supports broader clinical access and potential reimbursement considerations for ultra‑deep whole genome tumor profiling in myeloid malignancies.
Caris ChromoSeq is described as the first ultra‑deep WGS assay for AML, MDS, MPN and related myeloid cancers, consolidating multiple tests into a single comprehensive report to aid diagnosis and treatment decisions.
Caris Life Sciences (NASDAQ: CAI) published a peer-reviewed study validating an AI-derived signature that predicts MGMT promoter methylation and temozolomide (TMZ) benefit in glioblastoma (GBM) patients.
The signature was developed from a clinico-genomic dataset of 5,841 patients and evaluated prospectively in >3,400 cases, showing high concordance with pyrosequencing and stratifying overall survival in TMZ-treated, IDH-wild type GBM.
Caris Life Sciences (NASDAQ: CAI) will present at the BofA Securities 2026 Health Care Conference and the Goldman Sachs 47th Annual Global Healthcare Conference.
Presentations: May 12, 2026, 10:00–10:30 AM PT (BofA, Las Vegas) and June 8, 2026, 10:40–11:15 AM ET (Goldman Sachs, Miami). Live and replay webcasts will be available on the company investor relations website.
Caris Life Sciences (NASDAQ: CAI) announced it will report first quarter 2026 financial results on Thursday, May 7, 2026. A live webcast will begin at 3:30 p.m. CT (4:30 p.m. ET) to discuss results, with a replay posted on the company investor relations website shortly after the call.